Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$70.30

1.73 (2.52%)

, MDCO

The Medicines Co.

$38.51

0.32 (0.84%)

16:34
10/05/16
10/05
16:34
10/05/16
16:34

Alnylam ends revusiran development after nerve damage risk

Alnylam Pharmaceuticals (ALNY) announced that, upon the recommendation of the ENDEAVOUR Phase 3 study data monitoring committee to suspend dosing, the company has decided to discontinue development of revusiran, an investigational RNA interference therapeutic that was being developed for the treatment of hereditary ATTR amyloidosis with cardiomyopathy. "This decision was made yesterday evening and has been communicated to investigators, study sites, and regulatory authorities. Following recent reports in the Phase 2 OLE study of new onset or worsening peripheral neuropathy, the ENDEAVOUR DMC assembled yesterday at the company's request to review these reports and ENDEAVOUR data on an unblinded basis. The DMC did not find conclusive evidence for a drug-related neuropathy signal in the ENDEAVOUR trial, but informed the company that the benefit-risk profile for revusiran no longer supported continued dosing. The company subsequently reviewed unblinded ENDEAVOUR data which revealed an imbalance of mortality in the revusiran arm as compared to placebo... We remain committed to serving the needs of the ATTR amyloidosis community," the company explained. The company noted it will "continue to evaluate ENDEAVOUR data to understand the potential cause of these findings." The decision to discontinue development of revusiran does not affect patisiran, which is currently in Phase 3 development for the treatment of hATTR amyloidosis with polyneuropathy, or any other Alnylam investigational RNAi therapeutic program in development. Based on a current assessment of the safety data across the company's other programs, which include the ALN-PCSsc program partnered with The Medicines Company (MDCO), there is no evidence of a drug-related neuropathy signal in over 800 treated subjects and patients with exposure of up to 34 months. The company reaffirms its "Alnylam 2020" guidance and remains committed to the advancement of these investigational RNAi therapeutics.

ALNY

Alnylam

$70.30

1.73 (2.52%)

MDCO

The Medicines Co.

$38.51

0.32 (0.84%)

  • 14

    Oct

  • 06

    Nov

ALNY Alnylam
$70.30

1.73 (2.52%)

08/22/16
WEDB
08/22/16
NO CHANGE
WEDB
Intellia Therapeutics data positive, says Wedbush
Wedbush analyst David Nierengarten says that additional data on Intella's (NTLA) TTR program in mice was "meaningful" and indicates that the program compares favorably with competing products. The analyst says that competing programs, including those of Alnylam (ALNY) and Ionis (IONS) have shown "only a transient benefit." He reiterates a $38 price target and Outperform rating on Intella.
09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
09/15/16
FBRC
09/15/16
INITIATION
Target $82
FBRC
Underperform
FBR calls Alexion overvalued, starts shares at Underperform
FBR Capital analyst Christopher James initiated coverage of Alexion Pharmaceuticals (ALXN) with an Underperform rating and $82 price target. The biotech focused on patients with ultra-rare disorders closed yesterday up $2.63 to $129.42. Alexion shares are overpriced as the company is facing a competitive near-term landscape, particularly from Alnylam's (ALNY) ALN-CC5, James tells investors in a research note. Further, near-term expansion into additional indications will be challenging given the recent failed study with eculizumab in refractory generalized myasthenia gravis, the analyst contends. He also sees possible pricing pressures from biosimilars, including an Amgen (AMGN) biosimilar product in development. James this morning also initiated Achillion Pharmaceuticals (ACHN) and Arena Pharmaceuticals (ARNA) with Outperform ratings.
09/28/16
JANY
09/28/16
INITIATION
Target $74
JANY
Neutral
Alnylam initiated with a Neutral at Janney Capital
Janney Capital analyst Roy Buchanan initiated Alnylam with a Neutral and a $74 fair value estimate. The analyst is not confident about the outcome for the pivotal study for patisiran in transthyretin familial amyloid neuropathy, expected in about 12 months, and give patisiran a 50% chance of success.
MDCO The Medicines Co.
$38.51

0.32 (0.84%)

05/13/16
JEFF
05/13/16
NO CHANGE
Target $43
JEFF
Buy
The Medicines Co. could rally $4/share on positive data, says Jefferies
Jefferies analyst Biren Amin says The Medicines Co. has a "catalyst-rich" second half of 2016, including the Phase III trials of Carbavance in complicated urinary tract infections and carbapenem resistant enterobacteriaceae infections. The analyst expects both of the trials will be successful and show non-inferiority leading to potential FDA approval. Amin thinks shares could move $3 to $4 per share on positive data readout. He keeps a Buy rating on The Medicines Co. with a $43 price target.
07/11/16
JEFF
07/11/16
NO CHANGE
Target $43
JEFF
Buy
Jefferies views The Medicines Co. ruling as positive surprise
Jefferies analyst Biren Amin views today's Court of Appeals ruling as a "positive surprise" for The Medicines Company. The ruling "breathes potential life" into the company's Angiomax patents, Amin tells investors in a research note. He expects Hospira to file an appeal within 90 days. The analyst has a Buy rating on The Medicines Co. with a $43 price target.
08/02/16
EVER
08/02/16
NO CHANGE
EVER
Buy
Pfizer shelves oral PCSK9, a Medicines Co. competitor, says Evercore ISI
Evercore ISI analyst Umer Raffat said Pfizer (PFE) management does not thin the profile for oral PCSK9 will be competitive with the strong efficacy of antibodies and have moved other interesting products forward. Raffat said some Medicines Co. (MDCO) investors had worried that a potential oral PCSk9 from Pfizer could greatly reduce enthusiasm for an every-6-month PCSk9 from MDCO. The analyst said the next catalyst for The Medicines Co. is A1 Milano readout this month. Raffat rates The Medicines Co. a Buy with a $52 price target.

TODAY'S FREE FLY STORIES

BA

Boeing

$179.43

1.99 (1.12%)

17:39
02/27/17
02/27
17:39
02/27/17
17:39
Hot Stocks
Boeing awarded $678.7M government contract »

The Boeing Co., St.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FRGI

Fiesta Restaurant

$25.95

-0.4 (-1.52%)

17:37
02/27/17
02/27
17:37
02/27/17
17:37
Hot Stocks
Fiesta Restaurant suspends sale evaluation process »

For the past four months,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

IPWR

Ideal Power

$2.40

-0.03 (-1.23%)

17:25
02/27/17
02/27
17:25
02/27/17
17:25
Earnings
Ideal Power reports Q4 EPS (29c), consensus (29c) »

Reports Q4 revenue $400K…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

KRA

Kraton Performance

$27.49

0.68 (2.54%)

17:25
02/27/17
02/27
17:25
02/27/17
17:25
Earnings
Kraton Performance reports Q4 EPS 29c, consensus 33c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 07

    Mar

FLGT

Fulgent Genetics

$11.46

0.23 (2.05%)

17:19
02/27/17
02/27
17:19
02/27/17
17:19
Earnings
Fulgent Genetics reports Q4 EPS 6c, consensus 4c »

Reports Q4 revenue $5.9M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONB

Old National Bancorp

$18.65

-0.05 (-0.27%)

, FMER

FirstMerit

17:18
02/27/17
02/27
17:18
02/27/17
17:18
Hot Stocks
Old National names Michael Woods principal accounting officer »

Old National Bancorp…

ONB

Old National Bancorp

$18.65

-0.05 (-0.27%)

FMER

FirstMerit

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WNC

Wabash

$21.06

0.21 (1.01%)

17:17
02/27/17
02/27
17:17
02/27/17
17:17
Syndicate
Breaking Syndicate news story on Wabash »

Wabash files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANTH

Anthera

$0.71

0.0142 (2.05%)

17:15
02/27/17
02/27
17:15
02/27/17
17:15
Earnings
Anthera reports Q4 EPS (36c), consensus (41c) »

The company ended the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$122.40

-0.33 (-0.27%)

17:13
02/27/17
02/27
17:13
02/27/17
17:13
Hot Stocks
Johnson & Johnson: DOJ inquires on Olysio, Massachusetts probes non-profit aid »

Johnson & Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 09

    Mar

  • 14

    Mar

  • 27

    Mar

ITGR

Integer

$36.95

0.55 (1.51%)

17:12
02/27/17
02/27
17:12
02/27/17
17:12
Hot Stocks
Integer announces Gary Haire joins company as CFO »

Integer Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

SHLM

A. Schulman

$33.75

0.05 (0.15%)

17:12
02/27/17
02/27
17:12
02/27/17
17:12
Hot Stocks
A. Schulman to open distribution center at Stryker, Ohio plant »

A. Schulman, Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

SWX

Southwest Gas

$85.54

0.24 (0.28%)

17:10
02/27/17
02/27
17:10
02/27/17
17:10
Earnings
Southwest Gas reports Q4 EPS $1.37, consensus $1.35 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DERM

Dermira

$34.18

0.98 (2.95%)

17:09
02/27/17
02/27
17:09
02/27/17
17:09
Hot Stocks
Dermira to present data from DRM04, olumacostat glasaretil clinical programs »

Dermira announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

ALB

Albemarle

$92.46

-0.47 (-0.51%)

17:08
02/27/17
02/27
17:08
02/27/17
17:08
Earnings
Albemarle sees FY17 adjusted EPS $4.00-$4.25, consensus $4.07 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 16

    Mar

ALB

Albemarle

$92.46

-0.47 (-0.51%)

17:06
02/27/17
02/27
17:06
02/27/17
17:06
Earnings
Albemarle reports Q4 adjusted cont ops EPS 78c, consensus 73c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 16

    Mar

RAIL

FreightCar America

$14.60

-0.04 (-0.27%)

17:06
02/27/17
02/27
17:06
02/27/17
17:06
Earnings
FreightCar America reports Q4 EPS 1c, consensus 14c »

Reports Q4 revenue $…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

ZTO

ZTO Express

$14.57

0.42 (2.97%)

17:05
02/27/17
02/27
17:05
02/27/17
17:05
Earnings
ZTO Express sees Q1 revenue $360M-$374.4M, consensus $380.54M »

Representing a 27.6% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

ZTO

ZTO Express

$14.57

0.42 (2.97%)

17:03
02/27/17
02/27
17:03
02/27/17
17:03
Earnings
ZTO Express reports Q4 EPS 15c, consensus 16c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

WUBA

58.com

$32.49

0.52 (1.63%)

17:02
02/27/17
02/27
17:02
02/27/17
17:02
Earnings
Breaking Earnings news story on 58.com »

58.com sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

GLAD

Gladstone Capital

$9.22

0.1 (1.10%)

17:01
02/27/17
02/27
17:01
02/27/17
17:01
Hot Stocks
Gladstone Capital announces investment in unified communications business »

Gladstone Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WUBA

58.com

$32.49

0.52 (1.63%)

17:01
02/27/17
02/27
17:01
02/27/17
17:01
Earnings
58.com reports Q4 adjusted EPS 0c, consensus (12c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

PRGO

Perrigo

$84.68

0.25 (0.30%)

16:57
02/27/17
02/27
16:57
02/27/17
16:57
Hot Stocks
Perrigo down 11% after results, FY17 guidance, CFO change »

In after-hours trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 21

    Mar

STZ

Constellation Brands

$157.80

-1.05 (-0.66%)

16:56
02/27/17
02/27
16:56
02/27/17
16:56
Hot Stocks
Breaking Hot Stocks news story on Constellation Brands »

Soroban Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APPF

AppFolio

$25.05

1.25 (5.25%)

16:55
02/27/17
02/27
16:55
02/27/17
16:55
Earnings
Breaking Earnings news story on AppFolio »

AppFolio sees FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

RDN

Radian Group

16:55
02/27/17
02/27
16:55
02/27/17
16:55
Syndicate
Breaking Syndicate news story on Radian Group »

Radian Group files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.